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BENEFITS OF A CLINICAL
PHARMACOKINETIC SERVICE IN
OPTIMISING PHENYTOIN USE IN
THE WESTERN CAPE
P Valodia, M A Seymour, B M Kies, P I Folb
Objectives. To study the benefits of a clinical
pharmacokinetic service in optimising phenytoin use in the
Western Cape.
Design. Assessment of the response to treatment was based
on the number of seizures during the 3 months before
entering the study (first baseline period), 3 months after
entering the study (second baseline period) and 3 months
before the termination of the study (test period). Patients
kept a seizure diary throughout the study. The Michaelis-
Menten model was used to calculate doses and predict
steady-state serum concentrations.
Setting. ine epilepsy clinics.
Subjects. One hundred and ninety-five (113 black and 82
coloured) compliant people with epilepsy receiving generic
phenytoin monotherapy.
Outcome measures. Reduction in seizure frequency and
adverse effects.
Results. A reduction in seizure frequency (64.8% compared
with pre-optimisation) was experienced by 64.9% of patients.
Mean seizure frequency was reduced from 3.39 to 1.18 per
month. Reductions in seizure frequency of 100% and more
than 50% were reported by 39.2% and 58.7% of patients,
respectively. Adverse effects of phenytoin were reduced from
20.5% at the first visit to 3.2% at the last visit.
Conclusion. The clinical pharrnacokinetic dosing service for
phenytoin applied in this study contributed significantly to
the success of epilepsy management.
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umerous investigators have shown the benefit of monitoring
serum phenytoin concentrations in maximising efficacy and in
reducing toxicity to a minimum. Optimal therapy with
phenytoin requires that its administration be tailored to each
patient.u Phenytoin is one of the few drugs where saturation of
the metabolising enzymes occurs at therapeutic serum
concentrations. Serum phenytoin concentrations do not change
in proportion to dose; instead a small increase in phenytoin
dose may result in a disproportionately large increase in serum
phenytoin concentration.'
A clinical pharmacokinetic service (CPKS) can play an
important role in effectively controlling epilepsy. A CPKS
involves the optimisation and individualisation of a patient's
dose and response. The primary objective of this study was to
show the benefits of a CPKS in optimising phenytoin use in the
Western Cape. Reductions in seizure frequency and adverse
effects were used as the therapeutic endpoints.
METHODS
Six day hospitals, a neurology outpatient clinic, the South
African ational Epilepsy League (SA [EL) protective
workshop and a school for people with epilepsy were chosen
for the study. All the clinics were situated in the Cape Town
area. The Day Hospital Organisation consists of health care
centres for outpatients, providing primary health care to low-
income people who are not covered by medical aid (health
insurance). Patients were enlisted after confirmation of the
diagnosis at and referral from a specialist neurology unit.
Written informed consent was obtained in each case before
entry to the study. Data were collected between August 1990
and July 1992.
Patients
All ambulant adults with epilepsy who routinely took
phenytoin as a single anticonvulsant (538 in number) were
screened for entry into the study. Of these, 332 were compliant,
and had serum phenytoin concentrations to be expected from
their daily drug dose. All 332 were included in assessment of
the adverse effects. Altogether 195 patients met the entry
criteria for assessing reduction in seizure frequency. In order to
evaluate oeizure frequency, two criteria were set for each
patient. Firstly, the patient needed to have participated in the
study for a minimum of 6 months, so that the baseline (control)
and test periods did not overlap; and secondly s/he needed to
have attended the clinic for no less than 6 consultations. All
patients received phenytoin monotherapy and each one was
seen individually by the pharrnacokinetic consultant as an
outpatient.
Compliance was assessed by means of comprehensive
patient interview, tablet count: checking the prescription chart,
correct completion of the patient's diary, and variation between
two serial serum phenytoin concentrations taken at different
.•
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Period Number of seizures
RESULTS
'Only patients who participated in the study for at least 6 months and who attended
the clinic for a minimum of 6 consultations were included in the analysis.
Table I. Total number of seizures experienced during the first and







only assessed if considered necessary by the consultant. The
patient and family or close friends were questioned as to
whether the patient staggered or had an ataxic gait. The time of
day when adverse effects occurred was noted, as was whether
or not these effects occurred concurrently. Less frequent and
serious adverse effects of phenytoin were recorded.
Table I presents the total number of seizures experienced
during the first and second baseline periods and the test
period. The percentage reduction in seizure frequency based on
the first and second baseline periods and an average of the two
are reported in Table 11. No meaningful difference was found
when the first or second baseline periods were compared with
the test period (66.4% and 63.2%, respectively). This was
surprising as patients received counselling and kept seizure
diaries during the second baseline period. It is possible,
however, that there was under-reporting of the number of
seizures during the first baseline period. When reduction in
seizure frequency was based on the average of the first and
second baseline periods, reductions of 60.1% and 69.5% were
obtained in black and coloured patients, respectively. In 79
patients the dose of phenytoin was adjusted within 3 months of
entering the study. As seizure frequency during this period
reflected the second baseline period, the reduction in seizure
frequency referred to above is an underestimate.
times after the same dose.; After steady state was attained, and
provided the variation between the t"vo serum phenytoin
concentrations after the same dose was less than 20%, the
patient was considered to be compliant."
Clinical phannacokinetic service
Altogether, 2 748 consultations were conducted. The Michaelis-
Menten model was used to calculate dose and to predict
steady-state serum phenytoin concentrations. This model uses
estimates of the maximum metabolic rate (Vm) and the
Michaelis-Menten constant (Km) of phenytoin to perform its
functions." Details of the service have been described
elsewherew
During the first interview demographic and medical data
were obtained from the hospital folder and from the patient.
This included concurrent medication, duration of therapy and
dose, alcohol intake, history of other diseases, history of
seizures and their frequency, description of seizures, previous
admissions to hospital, and drug history, with emphasis on
anticonvulsant therapy. The patient was given a diary to record
seizures, adverse effects and when phenytOin was taken.
Patients were seen once a month, with a few exceptions who
attended more frequently.
When necessary, the Bayesian method of drug dose
optimisation was used (OPT, version 4.1b, Clydesoft Statistical
and Scientific Software).1I A laptop computer was used at the
clinics to run the OPT programme. The most likely estimates of
Vm, Km and dose were determined, with doses calculated for
two target serum phenytoin concentrations. The nearest
practical dose attainable with 100 mg, 50 mg and 27 mg
phenytoin sodium was used, and the corresponding target
phenytOin concentration was calculated and reported. Dose





Based on the first baseline period
Based on the second baseline period
Based on the average of the first and
second baseline period
Table ll. Percentage reduction in seizure frequency (195 patients)
Percentage reduction in
Period seizures
Reduction in seizure frequency was grouped into five
categories, as indicated in Table 111. Of 195 patients who
satisfied the inclusion criteria, 64.9% experienced a reduction in
seizure frequency. The remainder (35.1%) were either seizure-
free on entering the study or experienced no drop in frequency.
Two patients reported an increase in number of seizures. This
was attributed to severe stress and was not considered a result
0.7 SAMJJuly 199 , Vo!.
Assessment of seizure frequency
Response to treatment was assessed over 3 months." This was
based on the number of seizures during the 3 months before
entering the study (first baseline period), 3 months after
entering the study (second baseline period) and 3 months
before the termination of the study (test period). The average
number of seizures occurring during the first and second
ba eline periods was taken as the initial frequency. To minimise
the influence of non-compliance, patients in the second
baseline period were given the same counselling and service as
mI in the test period.
Assessment of adverse effects
Adverse effects of phenytoin were assessed at every visit by
direct enquiry or by clinical examination. The main adverse
effects looked for were dizziness, diplopia, blurred vision,
nystagmus, tremor, slurred speech and ataxia. Lower limb
ataxia was assessed at every visit, but upper limb ataxia was
ORIGINAL ARTICLES
of the CPKS. A 100% reduction in seizure frequency was
reported by 39.2% of patients during the test period. Monthly
seizure frequencies (mean and range) for the first and second
baseline and test periods are reported in Table IV. The mean
monthly seizure frequency was reduced from 3.39 (range 0 - 4
to 1.18 (range 0 - 16), based on comparison with the average
number of seizures occurring during the first and second
baseline periods.
Table ill. Percentage reduction in seizure frequency grouped into
various categories (195 patients)"
same dose. Reduction in seizure frequency can be attributed
primarily to the CPKS and not to improved compliance. The
second baseline period was taken into consideration in order to
minimi e the influence of non-compliance on the interpretation
of results. The significant reduction in adverse effects of
phenytoin is noteworthy; as far as possible these adverse
effects were confirmed by serum phenytOin concentrations.
A number of clinicians change one anti-epileptic drug for
another without ensuring that treatment is optimal. This study
shows that a considerable improvement in seizure frequency
can be obtained by optimising phenytoin treatment.


















This study demonstrated the contribution of a CPKS in
optimising phenytoin use in people with epilepsy in the
Western Cape. CPKS effectiveness is reflected in the reduction
in seizure frequency, and in the reduced adverse effects
experienced. It is hoped that these findings will provide
impetus for the implementation of a pennanent CPKS to
optimise phenytoin use in this region.
Table IV. Mean seizure frequency per month for specific periods




First baseline 3.62 0-48
period
Second baseline 3.15 0-29
period
Test period 1.18 0-16
Patients whose seizure frequency had fallen from baseline
level by 50% or more in the test period were considered to have
had good improvement in seizure control. Less than 50%
reduction was regarded as poor to intermediate improvement."
According to these criteria,S .7% had good improvement in
seizure control.
At the first visit, 20.5% of patients had experienced adverse
effects considered to be related to phenytoin, while at the last
visit 3.2% had experienced adverse effects. The decision
regarding whether or not the adverse effects were related to
phenytoin was based on serum phenytoin concentration and
the clinical judgement of the consultant.
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•
This study shows the benefits of a CPKS in the reduction of
seizure frequency and adverse effect. Benefits of the service
were measured by clinical response and not by the
achievement of a target drug concentration as end-point.
Compliance was assessed, as far as possible, by serial serum
phenytoin concentrations taken at different times after the
